StreetInsider.com News Articles

Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26888841.html

Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26888841.html

Myriad Genetics (MYGN) PT Lowered to $3 at Wells Fargo

Mon, 03 Aug 2026 07:08:46 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $3.00 (from $5.50) while maintaining a Equal Weight rating.

Myriad Genetics (MYGN) PT Lowered to $4 at TD Cowen

Fri, 31 Jul 2026 09:09:51 -0400

TD Cowen analyst Kyle Boucher lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $4.00 (from $6.00) while maintaining a Hold rating.

Form 10-Q MYRIAD GENETICS INC For: Jun 30

Fri, 31 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260731/26847015.html

Form 10-Q MYRIAD GENETICS INC For: Jun 30

Fri, 31 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260731/26847015.html

Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance

Fri, 31 Jul 2026 01:08:44 -0400

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.25), $0.19 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $190.7 million versus the consensus estimate of $206.03 million.

GUIDANCE:

Myriad Genetics sees FY2026 revenue of $770-790 million, versus the consensus of $863.6 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance

Fri, 31 Jul 2026 01:08:44 -0400

GUIDANCE:

Myriad Genetics sees FY2026 revenue of $770-790 million, versus the consensus of $863.6 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

Form 8-K MYRIAD GENETICS INC For: Jul 30

Thu, 30 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260730/26843607.html

Form 8-K MYRIAD GENETICS INC For: Jul 30

Thu, 30 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260730/26843607.html

Myriad Genetics cuts 2026 revenue guidance after Q2 miss

Thu, 30 Jul 2026 16:07:50 -0400

Myriad Genetics, Inc. (NASDAQ: MYGN) reported second quarter 2026 revenue of $190.7 million, an 11% decline year-over-year, as the molecular diagnostics company lowered its full-year 2026 revenue guidance to $770 million–$790 million, according to a company press release.

The revenue decline reflected a 1% drop in total test volume and a 9% decrease in average revenue per test. The average revenue per test decline included an $11.0 million reduction resulting from changes in estimates of cash collections for tests completed in prior periods. Total test volumes for the quarter were 379,000, compared with 384,000 in the same period a year earlier.

Myriad Genetics cuts 2026 revenue guidance after Q2 miss

Thu, 30 Jul 2026 16:07:50 -0400

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Thu, 30 Jul 2026 16:05:00 -0400

Highlights

Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cycle initiatives expected to improve reimbursement predictability and performance.
Maintained strong laboratory operating performance while driving productivity and cost-per-test improvements designed to support industry-leading gross margins.
Momentum continues for the Cancer Care Continuum business with second quarter test volume growth of 6% year-over-year, the launch of Prolaris + AI for prostate cancer, the expansion of Precise MRD to include colorectal and renal cancers,

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Thu, 30 Jul 2026 16:05:00 -0400

Highlights

Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cycle initiatives expected to improve reimbursement predictability and performance.
Maintained strong laboratory operating performance while driving productivity and cost-per-test improvements designed to support industry-leading gross margins.
Momentum continues for the Cancer Care Continuum business with second quarter test volume growth of 6% year-over-year, the launch of Prolaris + AI for prostate cancer, the expansion of Precise MRD to include colorectal and renal cancers,

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Thu, 23 Jul 2026 09:05:00 -0400

SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter of 2026.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Thu, 23 Jul 2026 09:05:00 -0400

SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter of 2026.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website

Myriad Genetics launches four-in-one prenatal genetic screen

Tue, 21 Jul 2026 09:05:52 -0400

Myriad Genetics, Inc. (NASDAQ: MYGN) announced the commercial launch of its FirstGene Multiple Prenatal Screen, a lab test that runs four prenatal genetic screens simultaneously from a single blood draw, available as early as eight weeks gestation.
The test combines fetal chromosome screening, fetal single-gene screening, patient carrier screening, and fetal RhD screening into one integrated report. Results are expected to be delivered in approximately 10 days, according to the company's press release.
The fetal chromosome screen assesses risk for conditions including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), sex chromosome aneuploidies, and 22q11.2 microdeletion (DiGeorge syndrome).

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Tue, 21 Jul 2026 09:05:00 -0400

The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation
SALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of FirstGene ^® Multiple Prenatal Screen, the only lab test that runs four prenatal genetic screens simultaneously from a single blood draw as early as eight weeks gestation.^* The FirstGene screen delivers fetal chromosome screening, fetal single-gene screening, patient carrier screening and

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Tue, 21 Jul 2026 09:05:00 -0400

The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation
SALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of FirstGene ^® Multiple Prenatal Screen, the only lab test that runs four prenatal genetic screens simultaneously from a single blood draw as early as eight weeks gestation.^* The FirstGene screen delivers fetal chromosome screening, fetal single-gene screening, patient carrier screening and

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Thu, 02 Jul 2026 09:05:00 -0400

Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories
SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-analysis of Prolaris to date, showing the Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for patients with localized prostate cancer. This evidence supports the role of the Prolaris Biopsy Test in localized prostate cancer risk stratification to help inform initial

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

Thu, 02 Jul 2026 09:05:00 -0400

Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories
SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-analysis of Prolaris to date, showing the Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for patients with localized prostate cancer. This evidence supports the role of the Prolaris Biopsy Test in localized prostate cancer risk stratification to help inform initial

Form 4 MYRIAD GENETICS INC For: Jun 23 Filed by: Skovronsky Daniel

Tue, 23 Jun 2026 16:25:00 -0400
si-local-file:///var/storage/secattach/20260623/26679810.html

Form 4 MYRIAD GENETICS INC For: Jun 23 Filed by: Skovronsky Daniel

Tue, 23 Jun 2026 16:25:00 -0400
si-local-file:///var/storage/secattach/20260623/26679810.html

Myriad Genetics expands Precise MRD cancer test to three tumor types

Tue, 23 Jun 2026 09:05:55 -0400

Myriad Genetics (NASDAQ: MYGN) announced the expanded availability of its Precise MRD test to patients with breast, colorectal, and renal cancers, according to a company press release. More than 6 million people in the U.S. are living with these cancers, according to the National Cancer Institute.
Precise MRD is a whole-genome sequencing-based assay that tracks up to 1,000 patient-specific variants to measure circulating tumor DNA (ctDNA). The test is designed for use at multiple points in cancer care, including neoadjuvant monitoring, post-surgical assessment, and long-term surveillance.
Alongside the expansion, Myriad published results from the prospective, multi-center MONITOR-Breast study in Future Oncology. The

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Tue, 23 Jun 2026 09:05:00 -0400

Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
SALT LAKE CITY, June 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients undergoing treatment and surveillance for breast, colorectal and renal cancers. More than 6 million individuals are living with these cancers in the U.S., representing a significant expansion in access to Myriad’s ultrasensitive Precise MRD test¹.

Precise MRD is a next-generation, ultrasensitive, whole-genome sequencing-based assay that generates a personalized